CERo Therapeutics to effect 1-for-100 reverse stock split to cure Nasdaq bid price deficiency

CERO THERAPEUTICS HOLDINGS, INC.

Reverse stock split at 1-for-100 ratio effective Jan 8, 2025; reduces outstanding shares from ~260M to ~2.6M.
Company received Nasdaq delisting notice on Oct 24, 2024 after bid price ≤$0.10 for ten consecutive days.
Company presented compliance plan to Nasdaq on Dec 17, 2024; believes reverse split will cure deficiency.
No fractional shares issued; stockholders entitled to fractional shares will round up to whole share.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

CERO THERAPEUTICS HOLDINGS, INC.: Amended certificate of incorporation to effect a 1-for-100 reverse stock split (effective 2025-01-08).

Change: charter amendment
Effective: 2025-01-08

Exact text from the filing

On January 6, 2025, CERo Therapeutics Holdings, Inc. (the “Company”) filed an amendment (the “Certificate of Amendment”) to its Second Amended and Restated Certificate of Incorporation, as amended and/or restated from time to time, to effectuate a reverse stock split of the Company’s issued and outstanding shares of common stock, par value $0.0001 per share (the “Common Stock”).

View on SEC.gov

89 governance changes filed in the last 30 days. Browse all governance changes →

CERO THERAPEUTICS HOLDINGS, INC. filing history →

Source: SEC EDGAR

accession 0001213900-25-001156

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.